Amedisys Inc (NASDAQ:AMED) insider David B. Pearce sold 398 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total value of $48,440.58. Following the completion of the sale, the insider now owns 11,818 shares in the company, valued at approximately $1,438,368.78. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
AMED stock traded down $0.29 on Thursday, reaching $121.81. The company had a trading volume of 1,801 shares, compared to its average volume of 325,371. Amedisys Inc has a 1 year low of $45.60 and a 1 year high of $126.30. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.21 and a current ratio of 1.21. The firm has a market cap of $3.93 billion, a P/E ratio of 55.49, a PEG ratio of 1.87 and a beta of 0.99.
Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, July 31st. The health services provider reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.22. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. The firm had revenue of $411.60 million for the quarter, compared to analyst estimates of $403.62 million. During the same quarter in the prior year, the company earned $0.62 EPS. research analysts predict that Amedisys Inc will post 3.41 earnings per share for the current year.
Institutional investors have recently modified their holdings of the business. Itau Unibanco Holding S.A. purchased a new position in shares of Amedisys during the 2nd quarter worth $149,000. SG Americas Securities LLC purchased a new position in shares of Amedisys during the 1st quarter worth $123,000. Moneta Group Investment Advisors LLC purchased a new position in shares of Amedisys during the 2nd quarter worth $181,000. Cubist Systematic Strategies LLC lifted its stake in shares of Amedisys by 1,086.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after purchasing an additional 2,172 shares during the period. Finally, Mount Yale Investment Advisors LLC purchased a new position in shares of Amedisys during the 1st quarter worth $151,000. 93.31% of the stock is currently owned by institutional investors.
AMED has been the topic of a number of research reports. Bank of America set a $139.00 price target on Amedisys and gave the stock a “buy” rating in a report on Tuesday, September 18th. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Stephens reaffirmed a “hold” rating and issued a $78.00 target price on shares of Amedisys in a research note on Tuesday, June 5th. Robert W. Baird upped their target price on Amedisys from $67.00 to $72.00 and gave the company a “neutral” rating in a research note on Tuesday, June 5th. Finally, Cantor Fitzgerald began coverage on Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 target price on the stock. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $86.46.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Story: Why do company’s buyback their stock?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.